The tweet was deleted by the author.
But we saved everything 🙂.
Kura Oncology has announced an investor webcast scheduled for October 13 at 4:30 p.m. ET to discuss the formation and launch of Caspian Therapeutics and to review preclinical data for KO-7246 presented at the 62nd EASD Annual Meeting.
The webcast will offer insights into Kura Oncology’s ongoing research and development efforts, particularly focused on menin-inhibitor therapies. The event reflects the company’s continued dedication to advancing its pipeline and sharing milestones with the investment community.
View post on X Loading...
Kura Oncology recently launched Caspian Therapeutics to focus on small-molecule menin inhibitors targeting diabetes and cardiometabolic diseases. The company's leadership team was bolstered earlier this year when Jennifer Fulk was appointed as chief financial officer. These developments highlight ongoing changes to Kura Oncology’s strategic direction.